Works by Chen, Chien‐Hung


Results: 194
    1
    2

    A Phase 3 clinical trial validating the potency and safety of an innovative, extra‐long‐acting interferon in chronic hepatitis C.

    Published in:
    JGH Open, 2022, v. 6, n. 11, p. 782, doi. 10.1002/jgh3.12825
    By:
    • Chen, Chi‐Yi;
    • Chuang, Wan‐Long;
    • Qin, Albert;
    • Zhang, Wen‐Hua;
    • Zhu, Li‐Ying;
    • Zhang, Guo‐Qiang;
    • Chen, Jyh‐Jou;
    • Lo, Ching‐Chu;
    • Zhou, Xinmin;
    • Mao, Xiaorong;
    • Shang, Jia;
    • Kuo, Hsing‐Tao;
    • Xie, Wen;
    • Chen, Chien‐Hung;
    • Lo, Gin‐Ho;
    • Jun, Dae W;
    • Dang, Shuangsuo;
    • Tsai, Chan‐Yen;
    • Wang, Ting‐Fang;
    • Lai, Hsin‐Hui
    Publication type:
    Article
    3
    4
    5
    6

    A Rotatable RBGW 3D Display.

    Published in:
    SID Symposium Digest of Technical Papers, 2012, v. 43, n. 1, p. 711, doi. 10.1002/j.2168-0159.2012.tb05882.x
    By:
    • Hsieh, Pei-Lin;
    • Kao, Meng-Chao;
    • Shen, Tzu-Chiang;
    • Chen, Chien-Hung;
    • Lin, Hsiang-Tan
    Publication type:
    Article
    7
    8
    9
    10
    11
    12
    13
    14
    15

    Dynamic α-fetoprotein, platelets and AST-to-platelet ratio index predict hepatocellular carcinoma in chronic hepatitis C patients with sustained virological response after antiviral therapy.

    Published in:
    2016
    By:
    • Cheng-Kun Wu;
    • Kuo-Chin Chang;
    • Chao-Hung Hung;
    • Po-Lin Tseng;
    • Sheng-Nan Lu;
    • Chien-Hung Chen;
    • Jing-Houng Wang;
    • Chuan-Mo Lee;
    • Ming-Chao Tsai;
    • Ming-Tsung Lin;
    • Yi-Hao Yen;
    • Tsung-Hui Hu;
    • Wu, Cheng-Kun;
    • Chang, Kuo-Chin;
    • Hung, Chao-Hung;
    • Tseng, Po-Lin;
    • Lu, Sheng-Nan;
    • Chen, Chien-Hung;
    • Wang, Jing-Houng;
    • Lee, Chuan-Mo
    Publication type:
    journal article
    16
    17
    18

    A novel predictive score for hepatocellular carcinoma development in patients with chronic hepatitis C after sustained response to pegylated interferon and ribavirin combination therapy.

    Published in:
    Journal of Antimicrobial Chemotherapy (JAC), 2012, v. 67, n. 11, p. 2766, doi. 10.1093/jac/dks269
    By:
    • Chang, Kuo-Chin;
    • Hung, Chao-Hung;
    • Lu, Sheng-Nan;
    • Wang, Jing-Houng;
    • Lee, Chuan-Mo;
    • Chen, Chien-Hung;
    • Yen, Ming-Fang;
    • Lin, Sheng-Chieh;
    • Yen, Yi-Hao;
    • Tsai, Ming-Chao;
    • Tseng, Po-Lin;
    • Hu, Tsung-Hui
    Publication type:
    Article
    19
    20
    21
    22
    23
    24
    25
    27

    Five‐year comparative risk of hepatocellular carcinoma development under entecavir or tenofovir treatment‐naïve patients with chronic hepatitis B‐related compensated cirrhosis in Taiwan.

    Published in:
    Alimentary Pharmacology & Therapeutics, 2020, v. 52, n. 11/12, p. 1695, doi. 10.1111/apt.16116
    By:
    • Hu, Tsung‐Hui;
    • Yueh‐Hsia Chiu, Sherry;
    • Tseng, Po‐Lin;
    • Chen, Chien‐Hung;
    • Lu, Sheng‐Nan;
    • Wang, Jing‐Houng;
    • Hung, Chao‐Hung;
    • Kee, Kwong‐Ming;
    • Lin, Ming‐Tsung;
    • Chang, Kuo‐Chin;
    • Lin, Meng‐Chih;
    • Chien, Rong‐Nan
    Publication type:
    Article
    29
    30
    31
    32
    33
    34
    35
    36
    37
    38
    39
    40
    41
    42
    43
    44
    45
    46
    47
    48
    49
    50